-
LIGHT/TNFSF14 Protein, Human, Recombinant (His Tag), HPLC-verified
LIGHT/TNFSF14 Protein, Human, Recombinant (His Tag), HPLC-verified
- 中文名称：
- LIGHT/TNFSF14 Protein, Human, Recombinant (His Tag), HPLC-verified
- 英文名称：
- LIGHT/TNFSF14 Protein, Human, Recombinant (His Tag), HPLC-verified
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA259176
- 规格：
- 0.1 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
- 货期：
- 6-8周
- 纯度：
- >= 90% as determined by SDS-PAGE.
= 90% as determined by SEC-HPLC.
- 产品形式：
- Lyophilized from sterile PBS, pH 7.4.
Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14/LIGHT/CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin beta receptor (LTbetaR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14/LIGHT/CD258 also binds to a soluble non-signaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14/LIGHT/CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14/LIGHT/CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14/LIGHT/CD258 is being actively investigated as a possible basis for cancer treatment.
